ARK Invest's 2025 performance data shows the ARK Innovation ETF delivered a 35.5% return, significantly outperforming the S&P 500's 16.6% gain. Top performers included Robinhood Markets (+204%), Palantir Technologies (+135%), and AMD (+77%), while notable losers were The Trade Desk (-68%), Recursion Pharmaceuticals (-40%), and Twist Bioscience (-32%). ARK maintains conviction in underperforming positions based on long-term platform objectives.

The DNA computing market is projected to grow from $293.70 million in 2025 to $2.68 billion by 2032, with a 36.76% CAGR, driven by innovations in data storage, cryptography, and molecular computing technologies.

The global cell culture microcarriers market is projected to grow from USD 3.45 billion in 2025 to USD 7.2 billion by 2034, with an 8.54% CAGR, driven by advancements in biopharmaceuticals, cell therapies, and regenerative medicine research.

The DNA data storage market is expected to grow from $76 million in 2024 to $3,348 million by 2030, with a CAGR of 87.7%. The market is driven by increasing cybersecurity concerns and the need for secure, compact data storage solutions, particularly in healthcare and biotechnology sectors.

Twist Bioscience reported strong Q3 results with 18% revenue growth, achieving profitability through a one-time gain and improved operational efficiency. The company saw growth in Next Generation Sequencing and strategic product launches while managing slower Synthetic Biology segment performance.

The antibody discovery market is projected to grow at a 10% CAGR by 2032, driven by increasing chronic disease incidence, biologics adoption, and technological advancements in drug development.

The U.S. minimal residual disease testing market is projected to reach $2020 million by 2033, growing at a 9.38% CAGR, driven by rising cancer rates and advancements in precision medicine technologies like NGS and flow cytometry.

The global antibody discovery market size is anticipated to reach approximately USD 22,570 million by 2034, up from USD 9,570 million in 2025, expanding at a CAGR of 10% from 2025 to 2034. The growth is driven by the rising incidence of autoimmune and cancer diseases, rising preference for outsourcing in the pharmaceutical industry, and emerging disease targets.

The global RNA transcriptome profiling test market is expected to grow at a CAGR of 14.5% and reach a valuation of US$ 37,383.8 million by 2034, driven by increasing investments in biotechnology and genomics for the detection of chronic diseases.

The global gene panel market is projected to reach $11.75 billion by 2031, growing at a CAGR of 19.30% during the forecast period. The market growth is driven by advancements in genomic research, rising prevalence of genetic disorders, and growing awareness of genetic testing.

The DNA synthesis market is projected to grow significantly, driven by the increasing demand for DNA synthesis products and services across various applications, particularly in genomics research, personalized medicine, and therapeutic development.

The DNA synthesis market is forecasted to grow at a CAGR of 18.1% during 2023-2028, driven by increasing use of DNA synthesis-based therapeutics, technological innovations, and rising prominence of PCR solutions in the biomedical sector.